Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial

Multipotent Adult Progenitor Cells

Respiratory Distress ◽

Progenitor Cells ◽

Distress Syndrome ◽

Phase 1 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104277.560282 ◽

2008 ◽

Author(s):

Jozef Kesecioglu

Keyword(s):

Carboxylic Acid ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome*

Critical Care Medicine ◽

10.1097/ccm.0b013e318164e7e4 ◽

2008 ◽

Vol 36 (3) ◽

pp. 782-788 ◽

Cited By ~ 20

Author(s):

Peter E. Morris ◽

Peter Papadakos ◽

James A. Russell ◽

Richard Wunderink ◽

Daniel P. Schuster ◽

...

Keyword(s):

Carboxylic Acid ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome

http://isrctn.org/> ◽

10.1186/isrctn38366450 ◽

2013 ◽

Author(s):

Fang Gao

Keyword(s):

Respiratory Distress ◽

Intravenous Infusion ◽

Distress Syndrome ◽

Controlled Trial ◽

Double Blind ◽

Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00440-9 ◽

2021 ◽

Cited By ~ 1

Author(s):

Aurélien Mazeraud ◽

Matthieu Jamme ◽

Rossella Letizia Mancusi ◽

Claire Latroche ◽

Bruno Megarbane ◽

...

Keyword(s):

Respiratory Distress ◽

Distress Syndrome ◽

Intravenous Immunoglobulins ◽

Phase 3 ◽

Double Blind ◽

Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease

American Heart Journal ◽

10.1016/j.ahj.2020.05.010 ◽

2020 ◽

Vol 226 ◽

pp. 60-68 ◽

Cited By ~ 4

Author(s):

D. H. Frank Gommans ◽

Joris Nas ◽

Sara-Joan Pinto-Sietsma ◽

Yvonne Koop ◽

Regina E. Konst ◽

...

Keyword(s):

Clinical Trial ◽

Respiratory Distress ◽

Randomized Clinical Trial ◽

Distress Syndrome ◽

Hospitalized Patients ◽

Double Blind ◽

Double Blind Placebo ◽

Infection Disease

A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome

Intensive Care Medicine ◽

10.1007/s001340101077 ◽

2001 ◽

Vol 27 (10) ◽

pp. 1578-1583 ◽

Cited By ~ 57

Author(s):

Jean-Louis Vincent ◽

Rainer Brase ◽

Frederick Santman ◽

Peter Suter ◽

Angela McLuckie ◽

...

Keyword(s):

Respiratory Distress ◽

Prostaglandin E1 ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED. STUDY OF LIPOSOMAL PROSTAGLANDIN E1 (TLC C-53) IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME

Critical Care Medicine ◽

10.1097/00003246-199901001-00486 ◽

1999 ◽

Vol 27 (Supplement) ◽

pp. 164A ◽

Cited By ~ 3

Author(s):

Jean-Louis Vincent ◽

Rainer Brase ◽

Jean-Francois Dhainaut ◽

Angela McLuckie ◽

Frederik Santman ◽

...

Keyword(s):

Respiratory Distress ◽

Prostaglandin E1 ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30470-7 ◽

2021 ◽

Author(s):

Barry Dixon ◽

Roger J Smith ◽

Duncan J Campbell ◽

John L Moran ◽

Gordon S Doig ◽

...

Keyword(s):

At Risk ◽

Respiratory Distress ◽

Distress Syndrome ◽

Phase 3 ◽

Double Blind ◽

Treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study

Journal of Critical Care ◽

10.1016/s0883-9441(97)90029-0 ◽

1997 ◽

Vol 12 (4) ◽

pp. 177-182 ◽

Cited By ~ 104

Author(s):

Guido Domenighetti ◽

Peter M. Suter ◽

Marie-Denise Schaller ◽

Rudolf Ritz ◽

Claude Perret

Keyword(s):

Clinical Study ◽

Respiratory Distress ◽

Distress Syndrome ◽

Double Blind ◽

Double Blind Placebo ◽

Controlled Clinical Study

Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(17)30171-6 ◽

2017 ◽

Vol 5 (6) ◽

pp. 484-491 ◽

Cited By ~ 31

Author(s):

Daniel F McAuley ◽

LJ Mark Cross ◽

Umar Hamid ◽

Evie Gardner ◽

J Stuart Elborn ◽

...

Keyword(s):

Growth Factor ◽

Respiratory Distress ◽

Distress Syndrome ◽

Keratinocyte Growth Factor ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial